Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 16/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 14/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 16/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 14/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 14/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 13/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 13/20 | 0.41 |
| ▸ | HDAC10 | Q969S8 | 13/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 12/20 | 0.41 |
| ▸ | HDAC9 | Q9UKV0 | 12/20 | 0.41 |
| ▸ | HDAC5 | Q9UQL6 | 12/20 | 0.41 |
| ▸ | CEPT1 | Q9Y6K0 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6138543 | 1.00 | HDAC1 (0.47) | HDAC1HDAC8HDAC2HDAC3HDAC6 | |
| SCHEMBL6138391 | 0.86 | HDAC1 (0.47) | HDAC1HDAC8HDAC2HDAC3HDAC6 | |
| SCHEMBL6138874 | 0.86 | HDAC1 (0.47) | HDAC1HDAC8HDAC2HDAC3HDAC6 | |
| SCHEMBL6138770 | 0.84 | HDAC1 (0.54) | HDAC1HDAC8HDAC2HDAC3HDAC6 | |
| SCHEMBL6138395 | 0.84 | HDAC1 (0.54) | HDAC1HDAC8HDAC2HDAC3HDAC6 | |
| SCHEMBL6139026 | 0.84 | HDAC1 (0.54) | HDAC1HDAC8HDAC2HDAC3HDAC6 | |
| SCHEMBL6138487 | 0.79 | ESR1 (0.53) | HDAC1HDAC8HDAC2HDAC3HDAC6 | |
| SCHEMBL6138478 | 0.79 | ESR1 (0.53) | HDAC1HDAC8HDAC2HDAC3HDAC6 | |
| SCHEMBL6138500 | 0.76 | NPC1 (0.53) | HDAC1HDAC8HDAC2HDAC3HDAC6 | |
| SCHEMBL6138505 | 0.76 | NPC1 (0.53) | HDAC1HDAC8HDAC2HDAC3HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1215203-B1 | HYDROXAMIC ACID DERIVATIVES, PROCESS FOR THE PRODUCTION THEREOF AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO (JP) | 2005-02-16 | — | — | EP | claimed |
| US-20040214896-A1 | Hydroxamic acid derivatives, the methods for preparation thereof and pharmaceutical compositions comprising thereof, as an active ingredient | ONO PHARMACEUTICAL CO., LTD. | 2004-10-28 | — | — | US | claimed |
| EP-1215203-A1 | HYDROXAMIC ACID DERIVATIVES, PROCESS FOR THE PRODUCTION THEREOF AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-06-19 | — | — | EP | claimed |
| EP-1215203-B1 | HYDROXAMIC ACID DERIVATIVES, PROCESS FOR THE PRODUCTION THEREOF AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO (JP) | 2005-02-16 | — | — | EP | disclosed |
| US-20040214896-A1 | Hydroxamic acid derivatives, the methods for preparation thereof and pharmaceutical compositions comprising thereof, as an active ingredient | ONO PHARMACEUTICAL CO., LTD. | 2004-10-28 | — | — | US | disclosed |
| US-6770644-B1 | Hydroxamic acid derivatives, process for the production thereof and drug containing the same as the active ingredient | ONO PHARMACEUTICALS CO., LTD. (JP) | 2004-08-03 | — | — | US | disclosed |
| EP-1215203-A1 | HYDROXAMIC ACID DERIVATIVES, PROCESS FOR THE PRODUCTION THEREOF AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-06-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214896-A1 | Hydroxamic acid derivatives, the methods for preparation thereof and pharmaceutical compositions comprising thereof, as an active ingredient | HIF1AN, IL6, PYGM | HDAC1 942/4885HDAC8 1134/4885HDAC2 2590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.